PTC 299

Drug Profile

PTC 299

Alternative Names: PTC299

Latest Information Update: 03 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PTC Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • No development reported Breast cancer; CNS cancer; Neurofibromatoses; Solid tumours
  • Discontinued Kaposi's sarcoma

Most Recent Events

  • 09 Dec 2017 Preclinical trials in Acute myeloid leukaemia in USA (PO)
  • 09 Dec 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 27 Jan 2015 No development reported - Phase-I for Solid tumours (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top